Evidence map›Paper›PMID 38862832›Full record

ArticleCell biology and toxicology2024

HNRNPA2B1 stabilizes NFATC3 levels to potentiate its combined actions with FOSL1 to mediate vasculogenic mimicry in GBM cells.

Hanting Wang, Yiwen Shi, Xinxin Zhou, Lu Zhang, Aodan Yang, Dabo Zhou, Teng Ma

Abstract read
In one paragraph

Article in Cell biology and toxicology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. mActa pharmaceutica Sinica. B · 2025
    Review
  3. Review
  4. hnRNPA2B1 restrains granulosa cell ferroptosis by mJournal of ovarian research · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hanting WangDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang, 110122, China.
Yiwen ShiDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang, 110122, China.
Xinxin ZhouLiaoning University of Traditional Chinese Medicine, Shenyang, 110034, China.
Lu ZhangDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang, 110122, China.
Aodan YangThe First Clinical College of China Medical University, Shenyang, 110002, China.
Dabo ZhouSchool and Hospital of Stomatology, China Medical University, Shenyang, 110002, China. dbzhou@cmu.edu.cn.
Teng MaDepartment of Neurobiology, School of Life Sciences, China Medical University, Shenyang, 110122, China. mateng366@163.com.

Funding

Natural Science Foundation of Liaoning Province 2021-MS-158the General Project of Liaoning Province Education Department JYTMS20230121the Liaoning Province Applied Basic Research Program 2022JH2/101300013
6 · The paper itself

Abstract

backgroundVasculogenic mimicry (VM) is an enigmatic physiological feature that influences blood supply within glioblastoma (GBM) tumors for their sustained growth. Previous studies identify NFATC3, FOSL1 and HNRNPA2B1 as significant mediators of VEGFR2, a key player in vasculogenesis, and their molecular relationships may be crucial for VM in GBM.

aimsThe aim of this study was to understand how NFATC3, FOSL1 and HNRNPA2B1 collectively influence VM in GBM.

methodsWe have investigated the underlying gene regulatory mechanisms for VM in GBM cell lines U251 and U373 in vitro and in vivo. In vitro cell-based assays were performed to explore the role of NFATC3, FOSL1 and HNRNPA2B1 in GBM cell proliferation, VM and migration, in the context of RNA interference (RNAi)-mediated knockdown alongside corresponding controls. Western blotting and qRT-PCR assays were used to examine VEGFR2 expression levels. CO-IP was employed to detect protein-protein interactions, ChIP was used to detect DNA-protein complexes, and RIP was used to detect RNA-protein complexes. Histochemical staining was used to detect VM tube formation in vivo.

resultsFocusing on NFATC3, FOSL1 and HNRNPA2B1, we found each was significantly upregulated in GBM and positively correlated with VM-like cellular behaviors in U251 and U373 cell lines. Knockdown of NFATC3, FOSL1 or HNRNPA2B1 each resulted in decreased levels of VEGFR2, a key growth factor gene that drives VM, as well as the inhibition of proliferation, cell migration and extracorporeal VM activity. Chromatin immunoprecipitation (ChIP) studies and luciferase reporter gene assays revealed that NFATC3 binds to the promoter region of VEGFR2 to enhance VEGFR2 gene expression. Notably, FOSL1 interacts with NFATC3 as a co-factor to potentiate the DNA-binding capacity of NFATC3, resulting in enhanced VM-like cellular behaviors. Also, level of NFATC3 protein in cells was enhanced through HNRNPA2B1 binding of NFATC3 mRNA. Furthermore, RNAi-mediated silencing of NFATC3, FOSL1 and HNRNPA2B1 in GBM cells reduced their capacity for tumor formation and VM-like behaviors in vivo.

conclusionTaken together, our findings identify NFATC3 as an important mediator of GBM tumor growth through its molecular and epistatic interactions with HNRNPA2B1 and FOSL1 to influence VEGFR2 expression and VM-like cellular behaviors.

Indexed as

Cell MovementCell ProliferationGlioblastomaHeterogeneous-Nuclear Ribonucleoprotein Group A-BNeovascularization, PathologicNFATC Transcription FactorsProto-Oncogene Proteins c-fosAnimalsBrain NeoplasmsCell Line, TumorFos-Related Antigen 1Gene Expression Regulation, NeoplasticHumansMiceMice, NudeVascular Endothelial Growth Factor Receptor-2Fos-Related Antigen 1Heterogeneous-Nuclear Ribonucleoprotein Group A-BhnRNP A2KDR protein, humanNFATC3 protein, humanNFATC Transcription FactorsProto-Oncogene Proteins c-fosVascular Endothelial Growth Factor Receptor-2Gene expressionGlioblastoma (GBM)Transcription factorVasculogenic mimicry (VM)Xenograft

Identifiers

PMID38862832
PMCPMC11166796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.